Cronos Group Inc (NAS:CRON)
$ 3.04 +0.040 (+1.33%) Market Cap: 1.12 Bil Enterprise Value: 374.47 Mil PE Ratio: 15.20 PB Ratio: 1.06 GF Score: 86/100

Q2 2026 Cronos Group Inc Earnings Call Transcript

Aug 6, 2026 / 12:30 PM GMT
Release Date Price: $3.07 (+12.87%)

Key Points

Positve
  • Cronos Group Inc (CRON) delivered record net revenue, gross profit, and adjusted EBITDA in Q2 2026, with consolidated net revenue up 58% year-over-year to $53 million.
  • The company's Spinach brand continues to dominate the Canadian market, holding the #1 position in vapes and edibles for multiple consecutive quarters, with significant market share gains across all product categories.
  • Cronos Group Inc (CRON)'s international expansion is gaining momentum, with record net revenue outside Israel growing 88% year-over-year, led by strong demand in Germany.
  • The company maintains a fortress balance sheet with $827 million in cash and investments, generating $24 million in positive cash flow from operations while actively repurchasing shares.
  • Cronos Group Inc (CRON)'s Israel operations delivered its 10th consecutive quarter of record net revenue, growing 60% year-over-year, with the Peace Naturals brand expanding its market leadership.
  • The pending acquisition of Canatalar in the Netherlands is progressing, which would provide entry into the largest adult-use cannabis program in Europe and create opportunities for the Spinach brand.
Negative
  • Cronos Group Inc (CRON) faces a new anti-dumping investigation in Israel regarding alleged dumping of medical cannabis imports from Canada, creating regulatory uncertainty despite the company's confidence in its defense.
  • The closing of the Canatalar acquisition has taken longer than expected due to the Dutch regulatory review process, with no specific timeline for completion beyond the second half of 2026.
  • Gross margins may be volatile quarter-to-quarter due to seasonality, product mix, and potential price compression, with the company cautioning that Q2's performance may not be sustainable.
  • Operating expenses increased year-over-year, driven by higher sales and marketing, R&D, and G&A costs, including transaction costs related to the Canatalar acquisition.
  • The company's stock liquidity remains thin despite its NASDAQ listing, reflecting broader investor focus on US markets and skepticism toward Canadian LPs, limiting capital market flexibility.
  • Cronos Group Inc (CRON) faces intense competition and price compression in key markets like Germany and Canada, requiring constant innovation and adaptation to maintain market share.


Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

CRON.TO - Cronos Group Inc.
Q2 2026 Cronos Group Inc Earnings Call
Aug 06, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good morning. My name is Haley, and I will be your conference operator today. I'd like to welcome everyone to Cronos' 2026 second quarter conference call. Today's call is being recorded.

At this time, I'd like to turn the call over to Harrison Aaron, Senior Director of Investor Relations and Corporate Development. Please go ahead.

--------------------------------------------------------------------------------
Unidentified_2 [2]
--------------------------------------------------------------------------------
Thank you, Haley. And thank you for joining us today to review Cronos' 2026 Q2 financial and business performance. Today, I am joined by our Chairman, President, and CEO, Mike Gorenstein, and our CFO,
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot